Name | 9-Aminocamptothecin |
Synonyms | AMinocaMptothecin 9-Aminocamptothecin 9-AMINO-CAMPTOTHECIN CAMPTOTHECIN, 9-AMINO- CAMPTOTHECIN, 9-AMINO-(RG) 9-Amino-20-(S)-camptothecin |
CAS | 91421-43-1 |
InChI | InChI=1/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1 |
InChIKey | FUXVKZWTXQUGMW-FQEVSTJZSA-N |
Molecular Formula | C20H17N3O4 |
Molar Mass | 363.37 |
Density | 1.55±0.1 g/cm3(Predicted) |
Melting Point | 142.0-145.0 °C |
Boling Point | 819.6±65.0 °C(Predicted) |
Flash Point | 449.5°C |
Solubility | DMSO : 3.33 mg/mL (9.16 mM; Need ultrasonic) |
Vapor Presure | 2.01E-28mmHg at 25°C |
Appearance | Light yellow to brown (Solid) |
Color | Light yellow to Yellow to Orange |
Merck | 14,431 |
pKa | 11.23±0.20(Predicted) |
Storage Condition | 2-8°C(protect from light) |
Refractive Index | 1.771 |
MDL | MFCD00909855 |
Physical and Chemical Properties | Yellow crystalline powder, soluble in organic solvents such as methanol, ethanol, DMSO, etc., is derived from the acuminata Decne of the Camptotheca tree of Davidia involucrata. The fruit. |
Use | Used as an anticancer drug |
In vitro study | In human breast (MCF-7), bladder (MGH-U1), and colon (HT-29) cancer cell lines, 9-Aminocamptothecin cytotoxicity increases with both higher drug concentrations and longer exposure times. Minimal cell killing is also observed unless 9-Aminocamptothecin concentrations exceeds a threshold of 2.7 nm. 9-Aminocamptothecin inhibits PC-3, PC-3M, DU145, and LNCaP cells with IC 50 values of 34.1, 10, 6.5, and 8.9 nM, respectively after 96 h of drug exposure. |
In vivo study | 9-amino-CPT (9-amino-20(S)-camptothecin) inhibits tumor growth at the lowest oral dose (0.35 mg/kg/day), whereas higher oral doses (0.75 and 1 mg/kg/day) and s.c. administration (4 mg/kg/week) causes tumor regression. 9-amino-CPT (9-amino-20(S)-camptothecin) is well tolerated at all doses, with no toxic death or weight loss of more than 10% observed in any group. 9-amino-CPT (9-amino-20(S)-camptothecin) induces complete remissions in 55 % of SCID mice engrafted with human myeloid leukemia. The oral and intravenous routes are equally effective. The results with this pre-clinical model support the evaluation of 9-Aminocamptothecin as antileukemic agent in a phase I trial in patients with AML. |
RTECS | UQ0490500 |
HS Code | 29349990 |